腺病毒介导的野生型p53基因治疗肿瘤研究进展  

Advances in adenovirus-mediated wild-type p53 gene therapy in human tumors

作　　者：郑小红[1] 何小平[2] 朱人敏[2] 

机构地区：[1]南京军区南京总医院药品科,江苏南京210002 [2]南京军区南京总医院消化内科,江苏南京210002

出　　处：《医学研究生学报》2007年第1期86-89,共4页Journal of Medical Postgraduates

基　　金：国家自然科学基金资助项目(批准号:306007307)

摘　　要：恶性肿瘤的发生与基因突变有密切关系。抑癌基因p53编码转录因子P53蛋白在调控癌基因表达、DNA合成和损伤修复以及细胞凋亡中起关键作用。已证实50%以上肿瘤细胞存在p53基因突变,p53被认为在肿瘤形成中起非常重要作用。p53基因治疗的目的是纠正恶性细胞中突变的p53基因功能,在多种肿瘤的体内外试验中显示出明显疗效。作者就这方面研究进展作一综述,重点讨论腺病毒介导的p53基因治疗。Malignant transformation is closely related to gene mutations. The tumor suppressor gene p53 codes for a transcription factor, P53 protein, plays a critical regulation role in oncogene expression, DNA synthesis and repair systems, and cell apoptosis. It has been demonstrated that p53 mutation occurs in more than 50% of cancer cells, which is thought to play a crucial role in malignant transformation, p53- based gene therapeutical approaches in vitro and in vivo aiming at a direct correction of the specific molecular defect in p53-mutated malignant cells, showed notable efficacy in numerous cancer types. In this review, we discussed the current advances in this field, focusing on adenovirus-mediated wild-type p53 gene therapy.

关 键 词：P53基因 基因治疗 腺病毒 肿瘤 

分 类 号：R730.5[医药卫生—肿瘤]